Skip to main content
SpringerLink
Log in

EpiPen OOP spending doubles, rebates avoided in US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

References

  1. Chua K-P, et al. Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014. JAMA Internal Medicine : 27 Mar 2017. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2017.0252.

  2. Luo J, et al. Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016. JAMA Internal Medicine : 27 Mar 2017. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2017.0257.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

EpiPen OOP spending doubles, rebates avoided in US. PharmacoEcon Outcomes News 775, 18 (2017). https://doi.org/10.1007/s40274-017-3882-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3882-2

Search

Navigation